Literature DB >> 16253902

Rare endocrine tumours of the GI tract.

Gerard M Doherty1.   

Abstract

Functional pancreatic endocrine tumors other than gastrinoma and insulinoma are quite rare. The principles of management include the diagnosis and management of the functional hormonal syndrome, and management of the potentially malignant tumor. Optimally, control of the hormonal syndrome is achieved preoperatively to stabilize the patient status for the operation, however, resection may be an important part of the control of the hormonal syndrome. Ultimately, the only curative treatment for these neoplasms is complete tumour resection, when feasible.

Entities:  

Mesh:

Year:  2005        PMID: 16253902     DOI: 10.1016/j.bpg.2005.05.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  13 in total

Review 1.  Neuroendocrine tumors of the gastro-entero-pancreatic system.

Authors:  Sara Massironi; Valentina Sciola; Maddalena Peracchi; Clorinda Ciafardini; Matilde Pia Spampatti; Dario Conte
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

2.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors.

Authors:  Gregory Kaltsas; Martyn Caplin; Philippa Davies; Diego Ferone; Rocio Garcia-Carbonero; Simona Grozinsky-Glasberg; Dieter Hörsch; Eva Tiensuu Janson; Reza Kianmanesh; Beata Kos-Kudla; Marianne Pavel; Anja Rinke; Massimo Falconi; Wouter W de Herder
Journal:  Neuroendocrinology       Date:  2017-03-02       Impact factor: 4.914

3.  Pancreatic and peripancreatic somatostatinomas.

Authors:  J M L Williamson; C C Thorn; D Spalding; R C N Williamson
Journal:  Ann R Coll Surg Engl       Date:  2011-07       Impact factor: 1.891

Review 4.  Rare and unusual endocrine cancer syndromes with mutated genes.

Authors:  Maya B Lodish; Constantine A Stratakis
Journal:  Semin Oncol       Date:  2010-12       Impact factor: 4.929

5.  Duodenal enteroglucagonoma revealed by differential comparison of serum and tissue glucagon reactivity with Siemens' Double Glucagon Antibody and DakoCytomation's Polyclonal Rabbit Anti-Human Glucagon: a case report.

Authors:  Wesley B Vanderlan; Ziying Zhang; Marwan S Abouljoud
Journal:  J Med Case Rep       Date:  2010-06-15

6.  Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreas.

Authors:  Raffaele Pezzilli; Davide Campana; Antonio-M Morselli-Labate; Maria-C Fabbri; Emilio Brocchi; Paola Tomassetti
Journal:  World J Gastroenterol       Date:  2009-10-28       Impact factor: 5.742

7.  Composite neuroendocrine and adenomatous carcinoma of the papilla of Vater.

Authors:  Joanna A Musialik; Maciej J Kohut; Tomasz Marek; Anatol Wodołazski; Marek Hartleb
Journal:  World J Gastroenterol       Date:  2009-09-07       Impact factor: 5.742

8.  Necrolytic migratory erythema as the first manifestation of pancreatic neuroendocrine tumor.

Authors:  Sheng-li Wu; Ji-gang Bai; Jun Xu; Qing-yong Ma; Zheng Wu
Journal:  World J Surg Oncol       Date:  2014-07-17       Impact factor: 2.754

Review 9.  Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.

Authors:  Bryan Oronsky; Patrick C Ma; Daniel Morgensztern; Corey A Carter
Journal:  Neoplasia       Date:  2017-11-05       Impact factor: 5.715

10.  The current strategy for managing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1.

Authors:  Yusuke Niina; Nao Fujimori; Taichi Nakamura; Hisato Igarashi; Takamasa Oono; Kazuhiko Nakamura; Masaki Kato; Robert T Jensen; Tetsuhide Ito; Ryoichi Takayanagi
Journal:  Gut Liver       Date:  2012-01-19       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.